Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Page 1
Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
Ascha M, Zhou X, Rao Y, Minai OA, Tonelli AR. Ascha M, et al. Among authors: minai oa. Cardiovasc Ther. 2017 Oct;35(5):10.1111/1755-5922.12281. doi: 10.1111/1755-5922.12281. Cardiovasc Ther. 2017. PMID: 28643420 Free PMC article.
Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS: We use observational long-term data on PAH patients treated with subcutaneous (SQ) treprostinil from a large o …
Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-spe …
Lung or Heart-Lung Transplant in Pulmonary Arterial Hypertension: What Is the Impact of Systemic Sclerosis?
Gadre SK, Minai OA, Wang XF, Zhang Q, Budev M, Tonelli AR. Gadre SK, et al. Among authors: minai oa. Exp Clin Transplant. 2017 Dec;15(6):676-684. doi: 10.6002/ect.2016.0209. Epub 2017 May 22. Exp Clin Transplant. 2017. PMID: 28540841 Free article.
Female sex (hazard ratio, 0.23; 95% confidence interval, 0.08-0.68) and less severe tricuspid regurgitation (hazard ratio, 0.31; 95% confidence interval, 0.11-0.89) were independently associated with long-term survival. CONCLUSIONS: Pulmonary arterial hypertension patients …
Female sex (hazard ratio, 0.23; 95% confidence interval, 0.08-0.68) and less severe tricuspid regurgitation (hazard ratio, 0.31; 95% confide …
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. ...The primary end point in a time-to-event analysis was the first event of clinical failure, whi …
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with p …
Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective.
Minai OA, Chaouat A, Adnot S. Minai OA, et al. Chest. 2010 Jun;137(6 Suppl):39S-51S. doi: 10.1378/chest.10-0087. Chest. 2010. PMID: 20522579
In patients with PH and advanced airflow limitation, lung transplantation offers the best opportunity for long-term benefit. The role of PH-specific medications remains poorly defined and requires further study but may be considered in patients with disproportionate PH....
In patients with PH and advanced airflow limitation, lung transplantation offers the best opportunity for long-term benefit. The role …
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group. Simonneau G, et al. Ann Intern Med. 2008 Oct 21;149(8):521-30. doi: 10.7326/0003-4819-149-8-200810210-00004. Ann Intern Med. 2008. PMID: 18936500 Clinical Trial.
OBJECTIVE: To investigate the effect of adding oral sildenafil to long-term intravenous epoprostenol in patients with pulmonary arterial hypertension. ...CONCLUSION: In some patients with pulmonary arterial hypertension, the addition of sildenafil to long-term intra …
OBJECTIVE: To investigate the effect of adding oral sildenafil to long-term intravenous epoprostenol in patients with pulmonary arter …
Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease.
Minai OA, Sahoo D, Chapman JT, Mehta AC. Minai OA, et al. Respir Med. 2008 Jul;102(7):1015-20. doi: 10.1016/j.rmed.2008.02.002. Epub 2008 Mar 17. Respir Med. 2008. PMID: 18343648 Free article.
None of the patients died during 1 year of follow-up. CONCLUSIONS: Epoprostenol and bosentan produced short-term functional benefit in our patients with PH and moderate or severe restrictive ILD. ...
None of the patients died during 1 year of follow-up. CONCLUSIONS: Epoprostenol and bosentan produced short-term functional benefit i …
Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Diaz-Guzman E, Heresi GA, Dweik RA, Minai OA. Diaz-Guzman E, et al. Among authors: minai oa. Respir Med. 2008 May;102(5):681-9. doi: 10.1016/j.rmed.2007.12.020. Epub 2008 Feb 14. Respir Med. 2008. PMID: 18280130 Free article.
BACKGROUND: Long-term follow-up after transition to oral agents from parenteral prostanoid therapy has not been well characterized. METHODS: We reviewed our long-term experience after oral transitioning in patients with pulmonary hypertension. ...
BACKGROUND: Long-term follow-up after transition to oral agents from parenteral prostanoid therapy has not been well characterized. M …
Treating pulmonary arterial hypertension: cautious hope in a deadly disease.
Minai OA, Budev MM. Minai OA, et al. Cleve Clin J Med. 2007 Nov;74(11):789-93, 797-800, 802 passim. doi: 10.3949/ccjm.74.11.789. Cleve Clin J Med. 2007. PMID: 18019999 Free article. Review.
Advances have brought cautious hope for patients with this progressive and deadly disease. Intravenous prostanoids are still the most effective long-term medications, but oral options are available for select patients who are closely monitored. ...
Advances have brought cautious hope for patients with this progressive and deadly disease. Intravenous prostanoids are still the most effect …
14 results